List of Publications by Year in descending order

120 papers	8,625 citations	76294 40 h-index	45285 90 g-index
125 all docs	125 docs citations	125 times ranked	11356 citing authors

#	Article	IF	Citations
1	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	1.2	2,392
2	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. JACC: Cardiovascular Interventions, 2015, 8, 1382-1392.	1.1	648
3	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2021, 325, 1620.	3.8	515
4	Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine, 2011, 364, 351-360.	13.9	325
5	A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism. JACC: Cardiovascular Interventions, 2018, 11, 1401-1410.	1.1	280
6	Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. Circulation, 2019, 140, e774-e801.	1.6	241
7	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 2060-2072.	1.2	230
8	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	1.8	206
9	The Acutely Decompensated Right Ventricle. Chest, 2005, 128, 1836-1852.	0.4	197
10	Recent Randomized Trials of Antithrombotic Therapy for PatientsÂWithÂCOVID-19. Journal of the American College of Cardiology, 2021, 77, 1903-1921.	1.2	150
11	Thromboangiitis Obliterans. Circulation, 2010, 121, 1858-1861.	1.6	146
12	Multidisciplinary Pulmonary Embolism Response Teams. Circulation, 2016, 133, 98-103.	1.6	129
13	Acute Pulmonary Embolism. Circulation, 2006, 114, e28-32.	1.6	128
14	Cerebral Venous Thrombosis. Circulation, 2012, 125, 1704-1709.	1.6	117
15	Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 2548.	3.8	117
16	Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series ofÂ115ÂPatients. Annals of Thoracic Surgery, 2015, 100, 1245-1252.	0.7	115
17	Management of Submassive Pulmonary Embolism. Circulation, 2010, 122, 1124-1129.	1.6	113
18	Fat Embolism Syndrome. Circulation, 2015, 131, 317-320.	1.6	105

#	Article	IF	Citations
19	Hospital Costs of Acute Pulmonary Embolism. American Journal of Medicine, 2013, 126, 127-132.	0.6	103
20	Venous Thromboembolism and Atherothrombosis An Integrated Approach. Circulation, 2010, 121, 2146-2150.	1.6	99
21	Anticoagulation-associated Adverse Drug Events. American Journal of Medicine, 2011, 124, 1136-1142.	0.6	92
22	Physician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patients. Circulation, 2009, 119, 2196-2201.	1.6	88
23	Double Trouble for 2,609 Hospitalized Medical Patients Who Developed Deep Vein Thrombosis. Chest, 2007, 132, 554-561.	0.4	87
24	Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. JAMA Internal Medicine, 2015, 175, 1112.	2.6	84
25	Venous Thromboembolism in Patients with Diabetes Mellitus. American Journal of Medicine, 2012, 125, 709-716.	0.6	83
26	Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 68-80.	1.0	81
27	Acute Pulmonary Embolism. Circulation, 2006, 114, e42-7.	1.6	80
28	Fibrinolysis for acute pulmonary embolism. Vascular Medicine, 2010, 15, 419-428.	0.8	61
29	Long-term complications of medical patients with hospitalacquired venous thromboembolism. Thrombosis and Haemostasis, 2009, 102, 688-693.	1.8	59
30	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American Heart Journal, 2022, 251, 43-53.	1.2	59
31	Venous thromboembolic events in hospitalised medical patients. Thrombosis and Haemostasis, 2009, 102, 505-510.	1.8	57
32	Mesenteric Venous Thrombosis. Circulation, 2015, 131, 1599-1603.	1.6	56
33	Adherence to Pharmacological Thromboprophylaxis Orders in Hospitalized Patients. American Journal of Medicine, 2010, 123, 536-541.	0.6	55
34	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis and Haemostasis, 2022, 122, 131-141.	1.8	55
35	Advanced Management of Intermediate- and High-Risk Pulmonary Embolism. Journal of the American College of Cardiology, 2020, 76, 2117-2127.	1.2	48
36	Pulmonary Embolism in Heart Failure. Circulation, 2008, 118, 1598-1601.	1.6	45

#	Article	IF	Citations
37	Patient Education Program for Venous Thromboembolism Prevention in Hospitalized Patients. American Journal of Medicine, 2012, 125, 258-264.	0.6	45
38	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. Journal of the American College of Cardiology, 2021, 78, 408-411.	1.2	44
39	Venous Thromboembolism in Heart Failure: Preventable Deaths During and After Hospitalization. American Journal of Medicine, 2011, 124, 252-259.	0.6	42
40	Submassive Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2013, 309, 171.	3.8	42
41	Computerized Decision Support for the Cardiovascular Clinician. Circulation, 2009, 120, 1133-1137.	1.6	40
42	Multi-screen electronic alerts to augment venous thromboembolism prophylaxis. Thrombosis and Haemostasis, 2010, 103, 312-317.	1.8	40
43	Heart Failure in Patients With Deep Vein Thrombosis. American Journal of Cardiology, 2008, 101, 1056-1059.	0.7	38
44	Deep vein thrombosis in patients with chronic kidney disease. Thrombosis and Haemostasis, 2008, 99, 1035-1039.	1.8	37
45	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. American Heart Journal, 2021, 235, 12-23.	1.2	36
46	Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). European Heart Journal, 2020, 41, 1086-1096.	1.0	35
47	Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. Journal of Thrombosis and Thrombolysis, 2008, 26, 35-40.	1.0	33
48	Deep-Vein Thrombosis in the Elderly. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 393-398.	0.7	33
49	Venous Thromboembolism in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Medicine, 2012, 125, 1010-1018.	0.6	33
50	Risk factors for major bleeding in the SEATTLE II trial. Vascular Medicine, 2017, 22, 44-50.	0.8	33
51	Vascular Teams in PeripheralÂVascularÂDisease. Journal of the American College of Cardiology, 2019, 73, 2477-2486.	1.2	32
52	Venous thromboembolism in patients with symptomatic atherosclerosis. Thrombosis and Haemostasis, 2011, 106, 1095-1102.	1.8	26
53	Optimal Duration of Anticoagulation After Venous Thromboembolism. Circulation, 2011, 123, 664-667.	1.6	26
54	Randomized Trial of Physician Alerts for Thromboprophylaxis after Discharge. American Journal of Medicine, 2013, 126, 435-442.	0.6	25

#	Article	IF	Citations
55	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	0.6	24
56	Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. Vascular Medicine, 2018, 23, 388-399.	0.8	24
57	One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2020, 13, e009012.	1.4	23
58	Underutilization of Anticoagulation for StrokeÂPrevention in AtrialÂFibrillation. Journal of the American College of Cardiology, 2016, 67, 2444-2446.	1.2	22
59	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22
60	Is Venous Thromboembolism a Chronic Inflammatory Disease?. Clinical Chemistry, 2015, 61, 313-316.	1.5	18
61	Surgical Pulmonary Embolectomy. Circulation, 2015, 132, 1146-1151.	1.6	18
62	Surgical pulmonary embolectomy and catheter-directed thrombolysis for treatment of submassive pulmonary embolism. Journal of Cardiac Surgery, 2018, 33, 252-259.	0.3	18
63	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. American Journal of Medicine, 2020, 133, 1-27.	0.6	18
64	Improving Clinical Effectiveness in Thromboprophylaxis for Hospitalized Medical Patients. American Journal of Medicine, 2009, 122, 230-232.	0.6	17
65	Thrombophilia Testing, Recurrent Thrombosis, and Womenâ€™s Health. Circulation, 2014, 130, 283-287.	1.6	17
66	Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. Human Reproduction, 2021, 36, 2083-2090.	0.4	17
67	Venous Thromboembolism in Hospitalized Patients With Active Cancer. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 469-475.	0.7	16
68	Beyond Virchowâ€™s Triad: Does cardiovascular inflammation explain the recurrent nature of venous thromboembolism?. Vascular Medicine, 2015, 20, 102-104.	0.8	16
69	Physician alerts to prevent venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2010, 30, 1-6.	1.0	15
70	Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. Vascular Medicine, 2016, 21, 361-368.	0.8	15
71	First-in-Human Study to Assess the Safety and Feasibility of the Bashir Endovascular Catheter for the Treatment of Acute Intermediate-Risk Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2021, 14, e009611.	1.4	15
72	Association of ABO blood group type with cardiovascular events in COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 51, 584-586.	1.0	14

#	Article	IF	Citations
73	Medication Use Evaluation: Pharmacist Rubric for Performance Improvement. Pharmacotherapy, 2014, 34, 5S-13S.	1.2	13
74	Quantification and Significance of Pulmonary Vascular Volume in Predicting Response to Ultrasound-Facilitated, Catheter-Directed Fibrinolysis in Acute Pulmonary Embolism (SEATTLE-3D). Circulation: Cardiovascular Imaging, 2019, 12, e009903.	1.3	13
75	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars in Thrombosis and Hemostasis, 2020, 46, 908-918.	1.5	13
76	A midterm report card for pulmonary embolism response teams. Vascular Medicine, 2018, 23, 72-74.	0.8	11
77	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Network Open, 2022, 5, e2215580.	2.8	11
78	Medicare's New Regulations for Deep Vein Thrombosis as a â€œNever Eventâ€: Wise or Worrisome?. American Journal of Medicine, 2009, 122, 975-976.	0.6	10
79	Handbook for Venous Thromboembolism. , 2015, , .		10
80	Thrombophilia, Inflammation, and Recurrent Pregnancy Loss: A Case-Based Review. Seminars in Reproductive Medicine, 2021, 39, 062-068.	0.5	10
81	Oh Heavy Burden: Recognizing the Risk of Venous Thromboembolism in Women Undergoing Assisted Reproduction. Thrombosis and Haemostasis, 2018, 118, 2011-2013.	1.8	9
82	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2021, 14, e012347.	1.3	9
83	Predictors of Treatment Response Following Ultrasound-Facilitated Catheter-Directed Thrombolysis for Submassive and Massive Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2020, 13, e008747.	1.4	8
84	Treatment Options in Massive and Submassive Pulmonary Embolism. Cardiology in Review, 2016, 24, 19-25.	0.6	7
85	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. TH Open, 2018, 02, e33-e38.	0.7	7
86	Venous Thromboembolism in Patients With Prior Stroke. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 43-49.	0.7	6
87	Computed tomography angiography with pulmonary artery thrombus burden and right-to-left ventricular diameter ratio after pulmonary embolism. Vascular, 2017, 25, 54-62.	0.4	6
88	Case 39-2021: A 26-Year-Old Woman with Respiratory Failure and Altered Mental Status. New England Journal of Medicine, 2021, 385, 2464-2474.	13.9	6
89	Venous Thromboembolism Guidebook. Critical Pathways in Cardiology, 2006, 5, 211-227.	0.2	5
90	Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2018, 45, 257-263.	1.0	5

#	Article	IF	Citations
91	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. Journal of the American Heart Association, 2021, 10, e021467.	1.6	4
92	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. Thrombosis and Haemostasis, 2022, 122, 1061-1070.	1.8	4
93	A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis. Journal of Visualized Experiments, 2015, , e52761.	0.2	3
94	Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. Vascular Medicine, 2017, 22, 324-330.	0.8	3
95	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. Current Emergency and Hospital Medicine Reports, 2018, 6, 54-61.	0.6	3
96	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. Journal of Thrombosis and Thrombolysis, 2019, 47, 331-335.	1.0	3
97	Thrombophilia, Antithrombotic Therapy, and Recurrent Pregnancy Loss: A Call for Pragmatism in the Face of Unknowns. Seminars in Reproductive Medicine, 2021, 39, 167-169.	0.5	3
98	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. Contemporary Clinical Trials, 2022, 115, 106714.	0.8	3
99	Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. Thrombosis Research, 2022, 214, 122-131.	0.8	3
100	Call for Formalized Pathways in VascularÂMedicine Training. Journal of the American College of Cardiology, 2022, 79, 2129-2139.	1.2	3
101	Risk Assessment to Predict Arterial and Venous Events in Patients Undergoing Percutaneous Coronary Intervention. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 478-483.	0.7	2
102	Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation. TH Open, 2018, 02, e229-e232.	0.7	2
103	Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy. Journal of Thrombosis and Thrombolysis, 2021, 52, 281-290.	1.0	2
104	Off the beaten path: the need for innovation in medical therapy to improve outcomes in acute pulmonary embolism. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 10-12.	0.4	2
105	Right Ventricular Recovery: Early and Late Changes after Acute PE Diagnosis. Seminars in Thrombosis and Hemostasis, 2023, 49, 797-808.	1.5	2
106	Pulmonary Embolism and Deep Vein Thrombosis. , 2013, , 580-595.		1
107	A fortune teller's dream or clinician's nightmare: Right ventricular assessment for risk prediction in pulmonary embolism. Thrombosis Research, 2020, 195, 169-170.	0.8	1
108	Stroke risk factors and outcomes among hospitalized women with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2021, 52, 1023-1031.	1.0	1

#	Article	IF	Citations
109	Response to Letter Regarding Article, â€œPhysician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patientsâ€. Circulation, 2009, 120, .	1.6	0
110	Thromboangiitis Obliterans (Buerger's Disease). , 2013, , 533-546.		0
111	Regulatory, legislative, and policy updates with anticoagulant use. Journal of Thrombosis and Thrombolysis, 2015, 39, 273-287.	1.0	0
112	Risk Factors for Venous Thromboembolism: Recognizing the Spectrum of Risk and Understanding the Role of Thrombophilia Testing. , 2015, , 7-14.		0
113	Response to Letter Regarding Article, â€œFat Embolism Syndromeâ€. Circulation, 2015, 132, e192.	1.6	0
114	Prevention of Venous Thromboembolism: An Evidence-Based Approach to Thromboprophylaxis. , 2015, , 123-134.		0
115	Trailblazing in pulmonary embolism research: the importance of extending beyond randomized controlled trials. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 237-239.	0.4	0
116	Pathophysiology of Deep Vein Thrombosis and Pulmonary Embolism: Beyond Virchowâ€™s Triad. , 2015, , 15-20.		0
117	Diagnosis of Pulmonary Embolism: An Integrated Approach to Clinical Evaluation, Laboratory Testing, and Imaging. , 2015, , 29-39.		0
118	Advanced Therapy for Venous Thromboembolism: Understanding the Role of Systemic Fibrinolysis, Catheter-Based Therapy, and Surgery. , 2015, , 51-65.		0
119	Anticoagulation for Venous Thromboembolism: Selecting the Optimal Parenteral and Oral Anticoagulant Regimen. , 2015, , 77-91.		0
120	Reply: The pathway to the â€˜truthâ€™ in the study of recurrent pregnancy loss and thrombophilia. Human Reproduction, 2021, 37, 191-193.	0.4	0